Maven Securities LTD Allogene Therapeutics, Inc. Transaction History

Maven Securities LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$6.78 - $12.28 $343,068 - $621,368	-50,600 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$7.65 - $15.29 $364,384 - $728,293	-47,632 Reduced 48.49%	50,600 $461,000
Q4 2021 Feb 14, 2022	BUY	$13.13 - $24.52 $1.29 Million - $2.41 Million	98,232 New	98,232 $1.47 Million
Q3 2020 Nov 13, 2020	SELL	$32.38 - $44.96 $6.48 Million - $8.99 Million	-200,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$18.39 - $54.04 $3.68 Million - $10.8 Million	200,000 New	200,000 $8.56 Million

176

132M

94.3K

112K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $403M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Maven Securities LTD, based on Form 13F filings with the SEC.

Stay updated on Maven Securities LTD with notifications on news.